• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用CRISPR/Cas9系统构建携带白细胞介素12和CXC趋化因子配体11的溶瘤单纯疱疹病毒用于结肠癌治疗

Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment.

作者信息

Zhang Nianchao, Li Jie, Yu Jingxuan, Wan Yajuan, Zhang Cuizhu, Zhang Hongkai, Cao Youjia

机构信息

College of Life Sciences, Key Laboratory of Microbial Functional Genomics of the Ministry of Education, Nankai University, 94 Weijin Road, Tianjin 300071, China.

State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, China.

出版信息

Virus Res. 2023 Jan 2;323:198979. doi: 10.1016/j.virusres.2022.198979. Epub 2022 Oct 23.

DOI:10.1016/j.virusres.2022.198979
PMID:36283533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10194376/
Abstract

Oncolytic viruses are an emerging cancer treatment modality with promising results in clinical trials. The new generation of oncolytic viruses are genetically modified to enhance virus selectivity for tumor cells and allow local expression of therapeutic genes in tumors. The traditional technique for viral genome engineering based on homologous recombination using a bacterial artificial chromosome (BAC) system is laborious and time-consuming. With the advent of the CRISPR/Cas9 system, the efficiency of gene editing in human cells and other organisms has dramatically increased. In this report, we successfully applied the CRISPR/Cas9 technique to construct an HSV-based oncolytic virus, where the ICP34.5 coding region was replaced with the therapeutic genes murine interleukin 12 (IL12, p40-p35) and C-X-C motif chemokine ligand 11 (CXCL11), and ICP47 gene was deleted. The combination of IL12 and CXCL11 in oncolytic viruses showed considerable promise in colorectal cancer (CRC) treatment. Overall, our study describes genetic modification of the HSV-1 genome using the CRISPR/Cas9 system and provides evidence from principle studies for engineering of the HSV genome to express foreign genes.

摘要

溶瘤病毒是一种新兴的癌症治疗方式,在临床试验中取得了令人鼓舞的结果。新一代溶瘤病毒经过基因改造,以增强病毒对肿瘤细胞的选择性,并使治疗性基因在肿瘤中局部表达。基于使用细菌人工染色体(BAC)系统进行同源重组的传统病毒基因组工程技术既费力又耗时。随着CRISPR/Cas9系统的出现,人类细胞和其他生物体中的基因编辑效率大幅提高。在本报告中,我们成功应用CRISPR/Cas9技术构建了一种基于单纯疱疹病毒(HSV)的溶瘤病毒,其中ICP34.5编码区被治疗性基因小鼠白细胞介素12(IL12,p40-p35)和C-X-C基序趋化因子配体11(CXCL11)取代,并且ICP47基因被删除。溶瘤病毒中IL12和CXCL11的组合在结直肠癌(CRC)治疗中显示出相当大的前景。总体而言,我们的研究描述了使用CRISPR/Cas9系统对HSV-1基因组进行基因改造,并为改造HSV基因组以表达外源基因的原理研究提供了证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/3791edf82e8b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/86287d806502/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/c2fcbcca04c0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/79813bc8523f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/93b6316ab0bb/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/3791edf82e8b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/86287d806502/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/c2fcbcca04c0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/79813bc8523f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/93b6316ab0bb/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f69c/10194376/3791edf82e8b/gr5.jpg

相似文献

1
Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment.利用CRISPR/Cas9系统构建携带白细胞介素12和CXC趋化因子配体11的溶瘤单纯疱疹病毒用于结肠癌治疗
Virus Res. 2023 Jan 2;323:198979. doi: 10.1016/j.virusres.2022.198979. Epub 2022 Oct 23.
2
Efficient Strategy for Synthesizing Vector-Free and Oncolytic Herpes Simplex Type 1 Viruses.高效合成无载体和溶瘤单纯疱疹病毒 1 型的策略。
ACS Synth Biol. 2024 Oct 18;13(10):3268-3280. doi: 10.1021/acssynbio.4c00360. Epub 2024 Oct 2.
3
Developing oncolytic through UL39 knockout by CRISPR-Cas9.通过CRISPR-Cas9敲除UL39来开发溶瘤病毒。
Iran J Basic Med Sci. 2020 Jul;23(7):937-944. doi: 10.22038/ijbms.2020.43864.10286.
4
A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.一种新型鸡尾酒疗法,基于携带白细胞介素-12、白细胞介素-15、GM-CSF、PD1v 和 IL-7×CCL19 的五重组合的溶瘤单纯疱疹病毒 2 载体,可增强抗肿瘤疗效。
Virol J. 2022 Apr 22;19(1):74. doi: 10.1186/s12985-022-01795-1.
5
Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.翻转 HSV-BAC:基于细菌人工染色体的系统,用于利用两种独立的位点特异性重组酶快速生成重组单纯疱疹病毒载体。
BMC Biotechnol. 2006 Sep 22;6:40. doi: 10.1186/1472-6750-6-40.
6
CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses.CRISPR-Cas9作为高效构建溶瘤病毒的强大工具。
Viruses. 2016 Mar 7;8(3):72. doi: 10.3390/v8030072.
7
Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.通过细菌人工染色体介导系统构建的携带白细胞介素18和可溶性B7-1双武装的三基因缺失溶瘤单纯疱疹病毒载体。
Cancer Res. 2005 Dec 1;65(23):10663-8. doi: 10.1158/0008-5472.CAN-05-2534.
8
Oncolytic virus therapy using genetically engineered herpes simplex viruses.使用基因工程单纯疱疹病毒的溶瘤病毒疗法。
Front Biosci. 2008 Jan 1;13:2060-4. doi: 10.2741/2823.
9
Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.利用CRISPR/Cas9基因敲除技术产生和验证重组1型单纯疱疹病毒(HSV-1)
Methods Enzymol. 2020;635:167-184. doi: 10.1016/bs.mie.2019.08.011. Epub 2019 Oct 18.
10
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.缺失ICP34.5基因的单纯疱疹病毒,具有增强的溶瘤、免疫刺激和抗肿瘤特性。
Gene Ther. 2003 Feb;10(4):292-303. doi: 10.1038/sj.gt.3301885.

引用本文的文献

1
CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics.CRISPR/Cas9在结直肠癌中的应用:通过基因组编辑和靶向治疗革新精准肿瘤学。
Iran J Basic Med Sci. 2025;28(10):1279-1300. doi: 10.22038/ijbms.2025.87531.18902.
2
Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.溶瘤单纯疱疹病毒疗法:最新进展、核心挑战与未来展望。
Vaccines (Basel). 2025 Aug 20;13(8):880. doi: 10.3390/vaccines13080880.
3
Oncolytic Viruses as a Novel Therapeutic Approach for Colorectal Cancer: Mechanisms, Current Advances, and Future Directions.
溶瘤病毒作为一种治疗结直肠癌的新型方法:作用机制、当前进展及未来方向
Cancers (Basel). 2025 May 31;17(11):1854. doi: 10.3390/cancers17111854.
4
Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment (Review).结直肠癌的精准溶瘤病毒疗法:用于个性化治疗的基因靶向和免疫调节(综述)
Int J Mol Med. 2025 Jul;56(1). doi: 10.3892/ijmm.2025.5545. Epub 2025 May 9.
5
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine.CRISPR-Cas技术进展及其应用:革新精准医学
Front Genome Ed. 2024 Dec 12;6:1509924. doi: 10.3389/fgeed.2024.1509924. eCollection 2024.
6
Control of HSV-1 Infection: Directions for the Development of CRISPR/Cas-Based Therapeutics and Diagnostics.单纯疱疹病毒 1 型感染的控制:基于 CRISPR/Cas 的治疗和诊断方法的发展方向。
Int J Mol Sci. 2024 Nov 17;25(22):12346. doi: 10.3390/ijms252212346.
7
Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy.白细胞介素-12递送策略与肿瘤免疫治疗进展
Curr Issues Mol Biol. 2024 Oct 16;46(10):11548-11579. doi: 10.3390/cimb46100686.
8
The investigation of oncolytic viruses in the field of cancer therapy.溶瘤病毒在癌症治疗领域的研究。
Front Oncol. 2024 Jul 10;14:1423143. doi: 10.3389/fonc.2024.1423143. eCollection 2024.
9
Designing molecules: directing stem cell differentiation.设计分子:引导干细胞分化
Front Bioeng Biotechnol. 2024 May 10;12:1396405. doi: 10.3389/fbioe.2024.1396405. eCollection 2024.
10
New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses.结直肠癌的新型免疫治疗方法:聚焦 CAR-T 细胞、双特异性抗体和溶瘤病毒。
Cell Commun Signal. 2024 Jan 19;22(1):56. doi: 10.1186/s12964-023-01430-8.